KMTS

KIRKLAND, Wash., April 22, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced it will exhibit at Heart Rhythm 2026, the annual meeting of the Heart Rhythm Society (HRS) taking place April 23–26 in Chicago. The company will showcase its Cardiac Recovery System® platform—a modern, integrated approach to managing sudden cardiac arrest (SCA) risk that unites proven therapy, actionable clinical insights, and ongoing patient support to enhance protection and optimize care. Kestra, one of the fastest-growing companies in medical technology, continues to build momentum as clinicians increasing

4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

KIRKLAND, Wash., April 09, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced it has been named a 2026 USA TODAY Top Workplaces award winner. "Being named a USA TODAY Top Workplace highlights a team dedicated to a meaningful purpose and mission with a commitment to making a real difference for patients and clinicians," said Brian Webster, President and CEO of Kestra Medical Technologies. "The opportunity to collaborate with people who share that responsibility creates strong alignment, defines our culture, and empowers our teams to work together to develop innovative, life-saving techn

SCHEDULE 13G/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)

S-3ASR - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

KIRKLAND, Wash., March 25, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced it has been named a finalist in the "Deal of the Year" category for the 2026 GeekWire Awards. Now in its 15th year, the annual awards recognize companies and leaders shaping the Pacific Northwest technology ecosystem, where Kestra continues to expand its presence. The "Deal of the Year" category recognizes impactful transactions including acquisitions, financings, and public offerings. Kestra was named a finalist for its successful 2025 initial public offering, a milestone that supports continued commercial e

4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

10-Q - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

KIRKLAND, Wash., March 17, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the third quarter fiscal 2026, which ended January 31, 2026. Financial Highlights Generated revenue of $24.6 million in Q3 FY26, an increase of 63% compared to the prior year period.Expanded gross margin to 52.6% in Q3 FY26 compared to 43.4% in the prior year period.Increased FY26 revenue guidance to $93 million, representing growth of 55% compared to FY25. "Kestra delivered another strong quarter of financial performance, generating revenue growth of 63% while expanding gross margin to

4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

KIRKLAND, Wash., March 03, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced that it will report third quarter fiscal 2026 financial results on Tuesday, March 17. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare comp

4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

SCHEDULE 13G/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)

SCHEDULE 13G/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)

SCHEDULE 13G - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)

4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced a strategic collaboration with Biobeat Technologies, Ltd. to expand diagnostic insight for patients prescribed the ASSURE® Wearable Cardioverter Defibrillator (WCD). The agreement is anchored by an exclusive license and co-development arrangement and includes a $5 million equity investment in Biobeat's recently announced Series B financing. Biobeat has developed the only clinically validated, FDA-cleared cuffless, patch-worn ambulatory blood pressure monitoring (ABPM) device, leveraging photoplethysmography-

4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

KIRKLAND, Wash., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 2:15 p.m. Pacific Time. Interested parties may access the live webcast and replay of the presentation by visiting the Kestra Medical Technologies investor relations website. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are int

10-Q - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today reported financial results for the second quarter fiscal 2026, which ended October 31, 2025. Financial Highlights Generated revenue of $22.6 million in Q2 FY26, an increase of 53% compared to the prior year period.Expanded gross margin to 50.6% in Q2 FY26 compared to 39.6% in the prior year period.Increased FY26 revenue guidance to $91 million, which would represent growth of 52% compared to FY25. "Kestra delivered another strong quarter of financial performance, generating revenue growth of 53% while expanding gross margin t